Evolocumab Reduced CV Events in Diabetes

Subgroup analysis of the VESALIUS-CV trial supports earlier intensive lipid lowering

1

Evolocumab significantly reduced the risk of major cardiovascular events in high-risk diabetes patients without known significant atherosclerosis.
2

In a trial with 12,257 patients, evolocumab lowered LDL cholesterol levels to a median of 52 mg/dL compared to 111 mg/dL with placebo.
3

The incidence of major adverse cardiovascular events was 5% in the evolocumab group versus 7% in the placebo group, showing a 2% absolute difference.
4

Evolocumab was associated with a 34% reduction in myocardial infarction and a 31% reduction in coronary heart disease death compared to placebo.
5

Serious adverse events occurred in similar rates between evolocumab (25%) and placebo (26%) groups, indicating comparable safety profiles.

1